Pasar al contenido principal

NUEVOS BIOMARCADORES EN NEOPLASIAS LINFOBLASTICAS DE CELULAS T PRECURSORAS: HETEROGENEIDAD INTRATUMORAL, EDITADO DEL ARNM Y EXOSOMAS

RTI2018-093330-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

  • Fernández-Navarro, Pablo
  • López-Nieva, Pilar
  • Piñeiro-Yañez, Elena
  • Carreño-Tarragona, Gonzalo
  • Martínez-López, Joaquín
  • Sánchez Pérez, Raúl
  • Aroca, Ángel
  • Al-Shahrour, Fátima
  • Cobos-Fernández, M. A.
  • Fernández-Piqueras, José
[Background] Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity of current protocols and the poor prognosis of patients with relapse or refractory make it urgent to find less toxic and more effective therapies in the context of a personalized medicine of precision., [Methods] Whole exome sequencing and RNAseq were performed on DNA and RNA respectively, extracted of a bone marrow sample from a patient diagnosed with tumour primary T-ALL and double negative thymocytes from thymus control samples. We used PanDrugs, a computational resource to propose pharmacological therapies based on our experimental results, including lists of variants and genes. We extend the possible therapeutic options for the patient by taking into account multiple genomic events potentially sensitive to a treatment, the context of the pathway and the pharmacological evidence already known by large-scale experiments., [Results] As a proof-of-principle we used next-generation-sequencing technologies (Whole Exome Sequencing and RNA-Sequencing) in a case of diagnosed Pro-T acute lymphoblastic leukaemia. We identified 689 disease-causing mutations involving 308 genes, as well as multiple fusion transcript variants, alternative splicing, and 6652 genes with at least one principal isoform significantly deregulated. Only 12 genes, with 27 pathogenic gene variants, were among the most frequently mutated ones in this type of lymphoproliferative disorder. Among them, 5 variants detected in CTCF, FBXW7, JAK1, NOTCH1 and WT1 genes have not yet been reported in T-ALL pathogenesis., [Conclusions] Personalized genomic medicine is a therapeutic approach involving the use of an individual’s information data to tailor drug therapy. Implementing bioinformatics platform PanDrugs enables us to propose a prioritized list of anticancer drugs as the best theoretical therapeutic candidates to treat this patient has been the goal of this article. Of note, most of the proposed drugs are not being yet considered in the clinical practice of this type of cancer opening up the approach of new treatment possibilities., This research was made possible through funding by the Spanish Ministry of Science, Innovation and Universities (RTI2018–093330-B_100); Spanish Ministry of Economy and Competitiveness (SAF2015–70561-R); MINECO/FEDER, EU; BES-2013-065740); Ramón Areces Foundation (CIVP19S7917); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association Against Cancer (AECC, 2018; PROYE18054PIRI); and the Institute of Health Carlos III, ISCIII (ACCI-CIBERER-17). Institutional grants from the Ramón Areces Foundation and the Santander Bank to the Severo Ochoa Molecular Biology Center (CBMSO) are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FADD in cancer: Mechanisms of altered expression and function, and clinical implications

  • Martín-Rubio, José L.
  • Vela-Martín, Laura
  • Fernández-Piqueras, José
  • Villa-Morales, María
FADD was initially described as an adaptor molecule for death receptor-mediated apoptosis, but subsequently it has been implicated in nonapoptotic cellular processes such as proliferation and cell cycle control. During the last decade, FADD has been shown to play a pivotal role in most of the signalosome complexes, such as the necroptosome and the inflammasome. Interestingly, various mechanisms involved in regulating FADD functions have been identified, essentially posttranslational modifications and secretion. All these aspects have been thoroughly addressed in previous reviews. However, FADD implication in cancer is complex, due to pleiotropic effects. It has been reported either as anti- or protumorigenic, depending on the cell type. Regulation of FADD expression in cancer is a complex issue since both overexpression and downregulation have been reported, but the mechanisms underlying such alterations have not been fully unveiled. Posttranslational modifications also constitute a relevant mechanism controlling FADD levels and functions in tumor cells. In this review, we aim to provide detailed, updated information on alterations leading to changes in FADD expression and function in cancer. The participation of FADD in various biological processes is recapitulated, with a mention of interesting novel functions recently proposed for FADD, such as regulation of gene expression and control of metabolic pathways. Finally, we gather all the available evidence regarding the clinical implications of FADD alterations in cancer, especially as it has been proposed as a potential biomarker with prognostic value., This work was supported by the Spanish Ministry of Economy and Competitiveness (RTI2018-093330-B-I00 and BES-2013-065740 to J.F.-P.); Fundación Ramón Areces to J.F.-P.; the Autonomous Community of Madrid, Spain (B2017/BMD-3778 LINFOMAS-CM to J.F.-P.); the Scientific Foundation of the Spanish Association against Cancer (AECC 2018 PROYE18054PIRI to J.F.-P.); the Instituto de Salud Carlos III (ACCI-CIBERER-17 ISCIII to J.F.-P.), and the Universidad Autónoma de Madrid, Faculty of Sciences (grants for final Master’s dissertation to M.V.-M.). L.V.-M. is the recipient of a Master’s fellowship from the Universidad Autónoma de Madrid, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia

  • Villa-Morales, María
  • Pérez-Gómez, Laura
  • Pérez-Gómez, Eduardo
  • López-Nieva, Pilar
  • Fernández-Navarro, Pablo
  • Santos, Javier
The standard-of-care treatment of T-cell acute lymphoblastic leukaemia (T-ALL) with chemotherapy usually achieves reasonable rates of initial complete response. However, patients who relapse or do not respond to conventional therapy show dismal outcomes, with cure rates below 10% and limited therapeutic options. To ameliorate the clinical management of these patients, it is urgent to identify biomarkers able to predict their outcomes. In this work, we investigate whether NRF2 activation constitutes a biomarker with prognostic value in T-ALL. Using transcriptomic, genomic, and clinical data, we found that T-ALL patients with high NFE2L2 levels had shorter overall survival. Our results demonstrate that the PI3K-AKT-mTOR pathway is involved in the oncogenic signalling induced by NRF2 in T-ALL. Furthermore, T-ALL patients with high NFE2L2 levels displayed genetic programs of drug resistance that may be provided by NRF2-induced biosynthesis of glutathione. Altogether, our results indicate that high levels of NFE2L2 may be a predictive biomarker of poor treatment response in T-ALL patients, which would explain the poor prognosis associated with these patients. This enhanced understanding of NRF2 biology in T-ALL may allow a more refined stratification of patients and the proposal of targeted therapies, with the ultimate goal of improving the outcome of relapsed/refractory T-ALL patients., This research was funded by grants from the Spanish Ministry of Science, Innovation, and Universities (RTI2018-093330-B-I00; MCIU/FEDER, EU to J.S.). Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms

  • Lahera, Antonio
  • López-Nieva, Pilar
  • Alarcón, Hernán
  • Marín-Rubio, José L.
  • Cobos-Fernández, M. A.
  • Fernández-Navarro, Pablo
  • Fernández, Agustín F.
  • Vela-Martín, Laura
  • Sastre, Isabel
  • Ruiz-García, Sara
  • Llamas, Pilar
  • López-Lorenzo, José L.
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
Despite the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway being frequently altered in T-ALL/LBL, no specific therapy has been approved for T-ALL/LBL patients with constitutive signalling by JAK/STAT, so there is an urgent need to identify pathway members that may be potential therapeutic targets. In the present study, we searched for JAK/STAT pathway members potentially modulated through aberrant methylation and identified SOCS3 hypermethylation as a recurrent event in T-ALL/LBL. Additionally, we explored the implications of SOCS3 deregulation in T-ALL/LBL and demonstrated that SOCS3 counteracts the constitutive activation of the JAK/STAT pathway through different molecular mechanisms. Therefore, SOCS3 emerges as a potential therapeutic target in T-ALL/LBL., This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to José Fernández-Piqueras and María Villa-Morales); Ministerio de Ciencia, Innovación y Universidades (RTI2018- 093330-B-I00; MCIU/FEDER, EU to José Fernández-Piqueras and Javier Santos); Fundación Ramón Areces (CIVP19S7917 to José Fernández-Piqueras); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to José Fernández-Piqueras); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to José Fernández-Piqueras); and Instituto de Investigación Sanitaria Fundación Jiménez Díaz to José Fernández-Piqueras; institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

  • Lahera, Antonio
  • Vela-Martín, Laura
  • López-Nieva, P.
  • Salgado, Rocío N.
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • López-Lorenzo, Jose L
  • Cornago, Javier
  • Llamas, Pilar
  • Fernández-Navarro, Pablo
  • Sánchez-Domínguez, Rebeca
  • Segovia, Jose C.
  • Sastre, Isabel
  • Cobos-Fernández, María
  • Menéndez, Pablo
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
descripción no proporcionada por scopus, This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to J.F.-P. and M.V.-M.); Ministerio de Ciencia, Innovación y Universidades (RTI2018-093330-B-I00; MCIU/FEDER, EU to J.F.-P. and J.S.); Fundación Ramón Areces (CIVP19S7917 to J.F.-P.); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to J.F.-P.); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to J.F.-P. and LABAE20049RODR to S.R-P.); Spanish National Research and Development Plan, Instituto de Salud Carlos III and FEDER (PI20/01837 to S.R.-P. and PI21/01641 to R.T.-R.); Proyecto Desarrollo Tecnológico (DTS19/00111 to S.R.-P.); Instituto de Investigación Sanitaria Fundación Jiménez Díaz to J.F.-P. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO; IAP-DRCLAS at Harvard and Fundación Asisa (086812) are also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Patterns of Differentially Expressed circRNAs in Human Thymocytes

  • López-Nieva, Pilar
  • Fernández-Navarro, Pablo
  • Cobos-Fernández, María Ángeles
  • González-Vasconcellos, Iria
  • Sánchez Pérez, Raúl
  • Aroca, Ángel
  • Fernández-Piqueras, José
  • Santos, Javier
Circular RNAs (circRNAs) are suggested to play a discriminative role between some stages of thymocyte differentiation. However, differential aspects of the stage of mature single-positive thymocytes remain to be explored. The purpose of this study is to investigate the differential expression pattern of circRNAs in three different development stages of human thymocytes, including mature single-positive cells, and perform predictions in silico regarding the ability of specific circRNAs when controlling the expression of genes involved in thymocyte differentiation. We isolate human thymocytes at three different stages of intrathymic differentiation and determine the expression of circRNAs and mRNA by RNASeq. We show that the differential expression pattern of 50 specific circRNAs serves to discriminate between the three human thymocyte populations. Interestingly, the downregulation of RAG2, a gene involved in T-cell differentiation in the thymus, could be simultaneously controlled by the downregulation of two circRNASs (hsa_circ_0031584 and hsa_circ_0019079) through the hypothetical liberation of hsa-miR-609. Our study provides, for the first time, significant insights into the usefulness of circRNAs in discriminating between different stages of thymocyte differentiation and provides new potential circRNA–miRNA–mRNA networks capable of controlling the expression of genes involved in T-cell differentiation in the thymus., This work was financed by grants from the Spanish Ministry of Science, Innovation and Universities (MCIU)(RTI2018- 093330-B-I00; MCIU/FEDER, EU), Ramón Areces Foundation (CIVP19S7917); Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association Against Cancer (AECC, 2018; PROYE18054PIRI); and the Spanish Ministry (Juan de la Cierva Grant IJCI-2016-29155). Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernández-Navarro, Pablo
  • Llamas, Pilar
  • López-Lorenzo, José L
  • Cornago, Javier
  • Santos, Javier
  • Fernández-Piqueras, José
  • Villa-Morales, María
Precursor T-cell neoplasms (T-ALL/LBL) are aggressive hematological malignancies that arise from the malignant transformation of immature thymocytes. Despite the JAK/STAT pathway is recurrently altered in these neoplasms, there are not pharmacological inhibitors officially approved for the treatment of T-ALL/LBL patients that present oncogenic JAK/STAT pathway mutations. In the effort to identify potential therapeutic targets for those patients, we followed an alternative approach and focused on their transcriptional profile. We combined the analysis of molecular data from T-ALL/LBL patients with the generation of hematopoietic cellular models to reveal that JAK/STAT pathway mutations are associated with an aberrant transcriptional profile. Specifically, we demonstrate that JAK/STAT pathway mutations induce the overexpression of the PIM1 gene. Moreover, we show that the pan-PIM inhibitor, PIM447, significantly reduces the leukemogenesis, as well as the aberrant activation of c-MYC and mTOR pathways in cells expressing different JAK/STAT pathway mutations, becoming a potential therapeutic opportunity for a relevant subset of T-ALL/LBL patients., This work was supported in part by funds from Ministerio de Economía y Competitividad (SAF2015-70561-R; MINECO/FEDER, EU to J.F.-P. and M.V.-M.); Ministerio de Ciencia, Innovación y Universidades (RTI2018- 093330-B-I00; MCIU/FEDER, EU to J.F.-P. and J.S.); Fundación Ramón Areces (CIVP19S7917 to J.F.-P.); Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM to J.F.-P.); Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI to J.F.-P.); and Instituto de Investigación Sanitaria Fundación Jiménez Díaz to J.F.-P.; institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBM are also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transient exposure to miR‐203 enhances the differentiation capacity of established pluripotent stem cells

  • Salazar‐Roa, María
  • Trakala, Marianna
  • Álvarez-Fernández, Mónica
  • Valdés‐Mora, Fátima
  • Zhong, Cuiqing
  • Muñoz, Jaime
  • Yu, Yang
  • Peters, Timothy J.
  • Graña‐Castro, Osvaldo
  • Serrano, Rosa
  • Zapatero-Solana, Elisabet
  • Abad, María
  • Bueno, María José
  • Gómez de Cedrón, Marta
  • Fernández-Piqueras, José
  • Serrano, Manuel
  • Blasco, María A.
  • Wang, Da‐Zhi
  • Clark, Susan J.
  • Izpisua‐Belmonte, Juan Carlos
  • Ortega, Sagrario
  • Malumbres, Marcos
Full differentiation potential along with self‐renewal capacity is a major property of pluripotent stem cells (PSCs). However, the differentiation capacity frequently decreases during expansion of PSCs in vitro. We show here that transient exposure to a single microRNA, expressed at early stages during normal development, improves the differentiation capacity of already‐established murine and human PSCs. Short exposure to miR‐203 in PSCs (miPSCs) induces a transient expression of 2C markers that later results in expanded differentiation potency to multiple lineages, as well as improved efficiency in tetraploid complementation and human–mouse interspecies chimerism assays. Mechanistically, these effects are at least partially mediated by direct repression of de novo DNA methyltransferases Dnmt3a and Dnmt3b, leading to transient and reversible erasure of DNA methylation. These data support the use of transient exposure to miR‐203 as a versatile method to reset the epigenetic memory in PSCs, and improve their effectiveness in regenerative medicine., M.S.R. was supported by the Asociación Española contra el Cáncer (AECC; 2012 AIOA120833SALA and 2018 INVES18005SALA) and a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU). M.T. was supported by Fundación La Caixa. M.A.F. was supported by MICIU (SAF2014‐60442‐JIN). J.F.P. was funded by MICIU (RTI2018‐093330‐B/FEDER‐EU), Ramón Areces Foundation (CIVP19S7917), CAM (B2017/BMD‐3778), and AECC (2018, PROYE18054PIRI). F.V.M was supported by the National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. Work in S.J.C laboratory was supported by the National Health and Medical Research Council (NHMRC 1063560). M.A.B. laboratory is funded by SAF2013‐45111‐R from MICIU, Fundación Botín and Banco Santander, and Worldwide Cancer Research (WCR16‐1177). Work in S.O. laboratory was funded by MICIU grant (SAF2013‐44866‐R). Work in the M.M. laboratory was supported by grants from the MICIU (RTI2018‐095582‐B‐I00, RED2018‐102723‐T, and SAF2017‐92729‐EXP), and the iLUNG Programme (B2017/BMD‐3884) from the Comunidad de Madrid. The CNIO is a Severo Ochoa Centers of Excellence (MICIU award SEV‐2015‐0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature

  • Lahera, Antonio
  • Vela-Martín, Laura
  • Fernández-Navarro, Pablo
  • López-Lorenzo, José Luis
  • Cornago, Javier
  • Llamas, Pilar
  • Fresno, Manuel
  • Santos, Javier
  • Villa-Morales, María
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggres-sive haematological malignancy that results from the malig-nant transformation of immature thymocytes and exhibitsa heterogeneous molecular landscape.1 Current standard-of-care treatments for T-ALL mainly consist of high-dosemulti-agent chemotherapy and achieve reasonable rates ofinitial complete responses that can reach up to 90% in chil-dren. However, refractory or relapsed patients have a dismalprognosis with survival rates below 10%; hence, most effortsare focused on optimizing first-line treatments and furtherimproving their efficacy. In this context, prognostic mark-ers capable of stratifying patients according to their poten-tial risk are essential, so high-risk patients may benefit frommore intensive chemotherapy regimens or haematopoieticstem cell transplantation, while low-risk patients may bene-fit from less intensive treatment approaches, which are char-acterized by reduced toxicity levels and fewer side effects, Ministerio de Ciencia, Innovación y Universidades, Grant/Award Number: RTI2018-093330-B-I00; Ministerio deEconomía y Competitividad, Grant/Award Number:SAF2015-70561-R; Instituto de Investigación Sanitaria Fundación Jiménez Díaz; Ministerio de Ciencia e Innovación,Grant/Award Number: PID2022-137487OB-I00.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

  • Lahera, Antonio|||0000-0002-8899-1376
  • Vela Martín, Laura|||0000-0001-9435-8668
  • López Nieva, Pilar|||0000-0001-6369-2444
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Torres-Ruiz, Rocío
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Cornago, Javier|||0000-0002-0737-4211
  • Llamas, Pilar
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Sánchez Domínguez, Rebeca
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Sastre, Isabel
  • Cobos Fernández, María Á.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Santos Hernández, Javier|||0000-0002-4168-6251
  • Fernández Piqueras, José
  • Villa Morales, María